|1.||Sinigaglia-Coimbra, Rita: 1 article (01/2011)|
|2.||Silva, Iara Ribeiro: 1 article (01/2011)|
|3.||Persike, Daniele Suzete: 1 article (01/2011)|
|4.||Vignoli, Thiago: 1 article (01/2011)|
|5.||Rosim, Fernanda Elisa: 1 article (01/2011)|
|6.||Ferrandon, Arielle: 1 article (01/2011)|
|7.||Nehlig, Astrid: 1 article (01/2011)|
|8.||Fernandes, Maria José da Silva: 1 article (01/2011)|
|9.||Jajoo, Sarvesh: 1 article (01/2010)|
|10.||Sheth, Sandeep: 1 article (01/2010)|
03/01/1991 - "L-Phenylisopropyladenosine was also found to protect mice against AOAA-induced convulsions, whereas atropine and baclofen had no effect. "
11/01/1987 - "Once kindled, various doses (0.001-0.5 microgram/0.5 microliter) of the adenosine analogs, L-phenylisopropyladenosine (L-PIA), N-ethylcarboximidoadenosine (NECA) or vehicle were injected into the seizure focus 5 min prior to electrical stimulation. "
07/05/1991 - "L-Phenylisopropyladenosine (L-PIA) and MK-801 also demonstrated anticonvulsant activity, with MK-801 also protecting the rats against the rapid death associated with pertussis toxin/pilocarpine-induced seizures. "
08/01/1985 - "The adenosine receptor agonists, 2-chloroadenosine (2-ClAdo), cyclohexyladenosine (CHA) and L- and D-phenylisopropyladenosine (L- and D-PIA), all produced dose-dependent elevations of the seizure threshold for pentylenetetrazol in rats. "
12/01/1989 - "The adenosine agonists, 5'-N-(ethyl)carboxamido-adenosine (NECA), cyclohexyladenosine, cyclopentyadenosine, 2-chloroadenosine and R- and S-phenylisopropyladenosine (R- and S-PIA), protected animals against seizures in a dose-dependent, and extremely potent manner. "
12/01/1995 - "Termination of the R-phenylisopropyladenosine treatment before ischemia eliminated its beneficial effects. "
05/01/1991 - "Metabolic effects of R-phenylisopropyladenosine during reversible forebrain ischemia studied by in vivo 31P nuclear magnetic resonance spectroscopy."
12/01/1995 - "Hearts treated with the adenosine A1 agonist R-phenylisopropyladenosine for 5 minutes immediately before ischemia exhibited both reduced infarct size (10% +/- 2%) and enhanced postischemic recovery of left ventricular developed pressure (86% +/- 3%). "
05/01/1991 - "The metabolic effects of R-phenylisopropyladenosine (R-PIA), an agonist of adenosine A1 receptors, were studied by in vivo 31P NMR spectroscopy before, during, and after 30 min of reversible forebrain ischemia in the rat. "
04/04/1994 - "Untreated rats and rats given the A1 receptor adenosine agonist, R-phenylisopropyladenosine (R-PIA), were subjected to four vessel ischemia. "
|3.||Ocular Hypertension (Glaucoma, Suspect)
05/01/1992 - "In New Zealand White rabbits, the topical administration of 500 micrograms of the relatively selective adenosine A1 receptor agonist R(-) phenylisopropyladenosine (R-PIA) produced a biphasic response in IOP in the ipsilateral eye: an initial ocular hypertension (3.5 +/- 1.4 mm of Hg) at 0.5 hour, followed by significant reduction in IOP (5 to 8 mm of Hg) from 2 to 6 hours postadministration. "
12/01/1998 - "Our study suggests such pain can be treated with a spinal injection of R-phenylisopropyladenosine in rats. "
07/01/2000 - "Marked enhancement of anti-allodynic effect by combined intrathecal administration of the adenosine A1-receptor agonist R-phenylisopropyladenosine and morphine in a rat model of central pain."
12/01/1998 - "Reduced anti-allodynic effect of the adenosine A1-receptor agonist R-phenylisopropyladenosine on repeated intrathecal administration and lack of cross-tolerance with morphine in a rat model of central pain."
12/01/1998 - "We examined the development of tolerance to the antiallodynic effect of chronic intrathecal (IT) administration of the adenosine analog R-phenylisopropyladenosine (R-PIA) in a rat model of central pain after ischemic spinal cord injury. "
07/29/1996 - "The aim of the present study was to investigate the effect of intravenous or intrathecal (i.t.) administration of R-phenylisopropyladenosine (R-PIA), a selective A1 adenosine receptor agonist, on spontaneous scratching behaviour, a phenomenon presumably related to pain in a mononeuropathy model (sciatic nerve ligation) in rats. "
|3.||Adenosine A1 Receptor
|8.||Valproic Acid (Valproate, Semisodium)
|9.||Purinergic P1 Receptors (Adenosine Receptor)